-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
The IASLC Provides More Than Just Scientific Knowledge at Tangier Conference
By Anna Wrona, MD, PhD Posted: October 2018 The IASLC Africa Conference on Lung Cancer 2018 in Tangier, Morocco, held last spring, provided participants with unique expert perspectives in lung cancer epidemiology, diagnostics, and treatment. This meeting created a collegial environment for open discussion among its international participants. The program offered a number of substantive…
-
Antoinette Wozniak, MD
Posted: October 2018 Antoinette Wozniak, MD, moved to Hillman Cancer Center at University of Pittsburgh Medical Center in September 2018, where she is now a professor of medicine, leader of the Lung Cancer Disease Team, and associate director of clinical research. She was previously with the Karmanos Cancer Institute for more than 25 years.
-
Raymond Osarogiagbon, MBBS, FACP
Posted: October 2018 Raymond Osarogiagbon, MBBS, FACP, has been selected as a member-elect to the Fleischner Society. Founded in 1969, the Fleischner Society is a collegial, multidisciplinary international thoracic imaging society dedicated to promoting education and research directed to innovative patient care. Dr. Osarogiagbon is director of the Multidisciplinary Thoracic Oncology Program at the Baptist…
-
After the Consultation: Social Media, Inter-Patient Communication, and Clinical Trials
By D. R. Camidge Posted: October 2018 Between March 2017 and April 2018, nearly 20,000 new members signed up for the Lung Cancer Survivors Support Community on Inspire. At present, membership of this online community is over 90,000 individuals from more than 200 different countries. Physicians have always known that patients continue discussions with friends…
-
Dr. James D. Cox
Posted: October 2018 James D. Cox, MD, a leader in the radiation oncology community and pioneer of proton therapy, passed away in August, just a month after his 80th birthday. Dr. Cox’s career path was peppered with illustrious mentors, directorships, society accolades, hundreds of peer-reviewed article publications, and an editorship of almost 2 decades. A…
-
Vassiliki A. Papadimitrakopoulou, MD
Posted: October 2018 Vassiliki A. Papadimitrakopoulou, MD, is the recipient of the 2018 Addario Lectureship Award presented by The Bonnie J. Addario Lung Cancer Foundation for her groundbreaking clinical research in immunotherapy. Dr. Papadimitrakopoulou is the Jay and Lori Eisenberg Distinguished Professor of Medicine at The University of Texas MD Anderson Cancer Center, where she…
-
Dr. David J. Sugarbaker
Posted: October 2018 David J. Sugarbaker, MD, an internationally known pioneer in the surgical management of malignant pleural mesothelioma and of complex thoracic cancers, passed away in August 2018 at the age of 66. Throughout his lifetime, Dr. Sugarbaker developed methods to perform intraoperative heated chemotherapy and refined extrapleural pneumonectomy techniques. Dr. Sugarbaker graduated top…
-
EGFR TKIs: A Marathon or Sprint?
By Edgardo S. Santos Castillero, MD, FACP Posted: October 2018 The approval of osimertinib in the frontline setting for patients with EGFR-sensitizing mutations has immediately challenged the decision-making process for oncologists. Osimertinib, a third-generation EGFR TKI, was initially developed as a specific therapy for EGFR T790M mutations, the most common mechanism of acquired resistance for…
-
Jessica S. Donington, MD, MSCR
Posted: October 2018 After 11 years at NYU Langone Health, Jessica S. Donington, MD, MSCR, has moved to the University of Chicago Medicine as professor of surgery and chief of the Section of Thoracic Surgery. In addition to her clinical practice, Dr. Donington is an avid researcher and respected leader in her field. Her research…
-
CAR-T Cells for Lung Cancer: Q&A with Dr. Charu Aggarwal
Posted: October 2018 With complete remissions seen in up to 90% of patients with B-cell acute lymphoblastic leukemia (ALL), a breakthrough therapy designation in multiple myeloma, and a first-of-its-kind approval for children and young adults with ALL, CAR-T cells have transformed the treatment landscape for hematologic malignancies. Progress in solid tumors, however, has been considerably…
View ILCN Archives
Provider Resources
Popular Articles